Veritas In Silico Inc. (130A.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.4x

Market Cap

JPY 2.82B

MomentumView details →

1D Return

+0.23%

YTD Return

−10.42%

RSI (14)

50.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.4x

Market Cap

JPY 2.82B

RSI (14)

50.9

MomentumView details →

1D Return

+0.23%

YTD Return

−10.42%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−39.42%

ROA (TTM)

−33.73%

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−76.83%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

7.79x

Quick Ratio

7.79x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

−602.00M

Op. CF (TTM)

—

Next earningsNov 13, 2026 →

Latest newsMore news →

Veritas In Silico opened the Kawasaki Research Institute in April 2026 by relocating and expanding facilities from the Shinkawasaki Research Institute, as part of strengthening its research infrastructure.30d ago

Veritas In Silico signed a contract with SpiroChem AG in May 2026 for joint exploratory research on mRNA-targeted compounds, following an agreement in December 2025.30d ago

Similar companies

Kringle Pharma,Inc.4884.T SymBio Pharmaceuticals Limited4582.T Modalis Therapeutics Corporation4883.T MUROMACHI CHEMICALS INC.4885.T CHUKYO IYAKUHIN CO.,LTD.4558.T Medrx Co.,Ltd.4586.T Find similar companies →

Latest newsMore news →

Veritas In Silico opened the Kawasaki Research Institute in April 2026 by relocating and expanding facilities from the Shinkawasaki Research Institute, as part of strengthening its research infrastructure.30d ago Veritas In Silico signed a contract with SpiroChem AG in May 2026 for joint exploratory research on mRNA-targeted compounds, following an agreement in December 2025.30d ago